Front Cover: Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors (ChemMedChem 9/2022)
ChemMedChem2022Vol. 17(9)
Linda Schäker‐Hübner, Reza Haschemi, Thomas Büch, Fabian B. Kraft, Birke Brumme, Andrea Schöler, Robert Jenke, Jens Meiler, Achim Aigner, Gerd Bendas, Finn K. Hansen
Abstract
The Front Cover shows the development of a potent and selective histone deacetylase 1 and 2 (HDAC1 and 2) inhibitor that was tailor-made to engage the characteristic “foot-pocket” present in both isoforms. This was achieved by a modular approach aiming to find the perfect balance between selectivity and drug-likeliness through systematic screening and thorough biological evaluation. Cover design by Dr. Christoph Selg. More information can be found in the Research Article by Linda Schäker-Hübner, Finn K. Hansen et al.
Related Papers
- → Isoform-Selective Histone Deacetylase Inhibitors(2008)99 cited
- → O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression(2016)48 cited
- → Proteomics-based trapping with single or multiple inactive mutants reproducibly profiles histone deacetylase 1 substrates(2022)3 cited
- → Optimal Substrate‐Trapping Mutants to Discover Substrates of HDAC1(2019)4 cited
- → ChemInform Abstract: Explorative Study on Isoform‐Selective Histone Deacetylase Inhibitors(2010)1 cited